SCHEMBL4467166

SCHEMBL4467166

CCOC(=O)CCCc1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.58
CYP4A11 Q02928 2/20 0.58
CYP4Z1 Q86W10 3/20 0.58
CYP4F11 Q9HBI6 1/20 0.58
CYP4F12 Q9HCS2 1/20 0.58
ALOX5 P09917 1/20 0.56
MAPK1 P28482 2/20 0.52
GAA P10253 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MAPT P10636 2/20 0.50
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17590526 0.95 CYP4Z1 (0.59) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL11039828 0.94 CYP4Z1 (0.58) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL95661 0.90 CYP4F2 (0.72) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL1417640 0.87 CYP4F2 (0.58) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL10289874 0.86 CYP4F2 (0.62) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL765000 0.86 CYP4F2 (0.62) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL765847 0.86 CYP4F2 (0.62) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL10736489 0.85 CYP4F2 (0.66) CYP4F2CYP4A11CYP4Z1MAPK1TDP1
SCHEMBL5050631 0.85 CYP4F2 (0.60) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12
SCHEMBL22334798 0.85 CYP4F2 (0.65) CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110300791-A Quantum dot dispersion, self-luminous photosensitive resin composition, color filter, and image display device 东友精细化工有限公司 2019-10-01 CN claimed
EP-2604595-B1 TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOUND THAT CONTAINS SAME AND EXHIBITS ANALGESIC ACTIVITY SHIONOGI & CO (JP) 2016-03-16 EP disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
EP-2111553-A2 OPTICAL BIOSENSORS Carnegie Mellon University (US) 2009-10-28 EP disclosed
WO-2008092041-A2 OPTICAL BIOSENSORS CARNEGIE MELLON UNIVERSITY (US) 2008-07-31 WO disclosed
US-3931279-A 5-Oxa prostaglandin F2.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 CYP4F2 116/4885CYP4A11 50/4885CYP4Z1 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.